XML 68 R53.htm IDEA: XBRL DOCUMENT v3.24.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of equity method investments (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
investment
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
investment
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Schedule of Equity Method Investments [Line Items]                    
Equity attributable to investee $ (218,336)       $ (218,336)       $ 291,117  
Revenues 148,365   $ 406,278   491,397   $ 838,368      
Net loss attributable to investees $ (433,604)   $ 46,381   $ (482,769)   $ 63,536      
Equity method investment, number of additional investments | investment   2       2        
Five Investments                    
Schedule of Equity Method Investments [Line Items]                    
Current assets   $ 51,858       $ 51,858       $ 51,588
Noncurrent assets   264,167       264,167       269,809
Current liabilities   9,080       9,080       8,594
Noncurrent liabilities   780       780       760
Noncontrolling interest   2,769       2,769       2,876
Revenues   40,478   $ 16,457   74,444   $ 44,428    
Cost of revenues   16,533   13,960   35,602   30,347    
Five Investments | Investee                    
Schedule of Equity Method Investments [Line Items]                    
Equity attributable to investee   303,396       303,396       309,167
Net loss attributable to investees   24,223   10,878   39,375   22,686    
FRG                    
Schedule of Equity Method Investments [Line Items]                    
Current assets   940,220       940,220       1,219,682
Noncurrent assets   2,995,502       2,995,502       3,142,660
Current liabilities   615,859       615,859       749,894
Noncurrent liabilities   2,609,036       2,609,036       2,695,445
Revenues   809,717       1,615,946        
Cost of revenues   511,723       1,011,402        
Loss from continuing operations   0       (1,175)        
FRG | Investee                    
Schedule of Equity Method Investments [Line Items]                    
Equity attributable to investee   710,827       710,827       917,003
Net loss attributable to investees   (19,256)       (188,839)        
B&W                    
Schedule of Equity Method Investments [Line Items]                    
Current assets   482,223       482,223       542,300
Noncurrent assets   313,300       313,300       294,979
Current liabilities   332,926       332,926       393,539
Noncurrent liabilities   685,064       685,064       585,430
Noncontrolling interest   544       544       626
Revenues   207,556   241,258   434,723   477,682    
Cost of revenues   159,075   189,329   330,627   372,089    
Loss from continuing operations   (15,799)   (12,686)   (70,065)   (14,975)    
Net loss attributable to investees   (16,791)   (12,475)   (79,515)   (6,815)    
B&W | Investee                    
Schedule of Equity Method Investments [Line Items]                    
Equity attributable to investee   (223,011)       (223,011)       (142,316)
Net loss attributable to investees   (16,833)   (12,496)   (83,287)   (10,475)    
Synchronoss Technologies, Inc.                    
Schedule of Equity Method Investments [Line Items]                    
Current assets   73,896       73,896       85,903
Noncurrent assets   224,607       224,607       275,304
Current liabilities   39,899       39,899       74,528
Noncurrent liabilities   163,344       163,344       166,673
Revenues   42,965   41,985   84,367   83,237    
Cost of revenues   10,223   10,960   20,515   22,959    
Synchronoss Technologies, Inc. | Investee                    
Schedule of Equity Method Investments [Line Items]                    
Equity attributable to investee   95,260       95,260       120,006
Net loss attributable to investees   2,341   (13,391)   (32,660)   (29,318)    
Other Equity Investments                    
Schedule of Equity Method Investments [Line Items]                    
Current assets   257,355       257,355       281,610
Noncurrent assets   502,904       502,904       627,858
Current liabilities   214,014       214,014       150,114
Noncurrent liabilities   129,047       129,047       277,638
Preferred stock   0       0       4,500
Revenues   109,929   37,512   255,903   75,435    
Cost of revenues   79,033   19,689   206,381   52,751    
Other Equity Investments | Investee                    
Schedule of Equity Method Investments [Line Items]                    
Equity attributable to investee   417,198       417,198       $ 477,216
Net loss attributable to investees   $ (5,469)   $ 10,728   $ (15,974)   $ (2,886)